Arikace amikacin: Extension study data

An interim DSMB review of 98 evaluable CF patients with chronic P. aeruginosa infection who completed the first year of the 2-year, open-label CLEAR-110 extension study showed that once-daily 560 mg Arikace was well tolerated and led to

Read the full 388 word article

How to gain access

Continue reading with a
two-week free trial.